The Claim
In individuals with obesity and prediabetes, administration of the GLP-1 receptor antagonist exendin(9-39) abolishes the insulin-sensitizing and glucose-lowering effects of liraglutide, demonstrating that these effects are specifically dependent on GLP-1 receptor activation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with obesity and prediabetes, blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose caused by liraglutide, showing that these effects require GLP-1 receptor activation.
See the scientific wording
In individuals with obesity and prediabetes, the GLP-1 receptor antagonist exendin(9-39) reverses the insulin-sensitizing and glucose-lowering effects of liraglutide, confirming that these benefits are specifically mediated through GLP-1 receptor activation and not through off-target or weight-loss-dependent mechanisms.
A drug that activates the GLP-1 receptor stops the liver from releasing too much sugar and helps muscles and fat absorb sugar better. When the GLP-1 receptor is blocked, the liver releases more sugar and the body becomes less responsive to insulin, undoing the benefits.
What the research says
1 studyWhen people took liraglutide, their blood sugar got better and their body used insulin more efficiently—but when they also took a drug that blocks the GLP-1 receptor, those improvements disappeared. This proves liraglutide works by activating the GLP-1 receptor, not just by helping people lose weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.